Cytomegalovirus breakthrough and resistance during letermovir prophylaxis
- PMID: 36693927
- DOI: 10.1038/s41409-023-01920-w
Cytomegalovirus breakthrough and resistance during letermovir prophylaxis
Abstract
Letermovir is a relatively new antiviral for prophylaxis against cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT). CMV-seropositive HCT recipients who received letermovir prophylaxis from 2018 to 2020 at our center were evaluated for letermovir resistance and breakthrough CMV reactivation. Two-hundred twenty-six letermovir recipients were identified and 7/15 (47%) with CMV DNAemia ≥200 IU/mL were successfully genotyped for UL56 resistance. A single C325Y resistance mutation was identified in an umbilical cord blood recipient. Ninety-five (42%), 43 (19%), and 15 (7%) patients had breakthrough CMV at any level, ≥150 IU/mL, and ≥500 IU/mL, respectively. Risk factors for breakthrough CMV reactivation at each viral threshold were examined. Cumulative steroid exposure was the strongest risk factor for CMV at all evaluated viral thresholds. Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide (aHR 2.34, 95% CI 1.28-4.28, p = 0.001) or calcineurin inhibitors plus mycophenolate (aHR 2.24, 95% CI 1.30-3.86, p = 0.004) were also associated with an increased risk of CMV reactivation at any level. De novo letermovir resistance is rare and can be successfully treated using other antivirals. Letermovir effectively prevents clinically significant CMV, however, subclinical CMV reactivation occurs frequently at our center.
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Similar articles
-
Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.BMC Infect Dis. 2019 May 8;19(1):388. doi: 10.1186/s12879-019-4016-1. BMC Infect Dis. 2019. PMID: 31068147 Free PMC article.
-
Outcomes of CMV infection in the setting of gastrointestinal graft-vs.-host disease in the era of pre-emptive and prophylactic antiviral therapy.Transpl Immunol. 2025 May;90:102232. doi: 10.1016/j.trim.2025.102232. Epub 2025 Apr 22. Transpl Immunol. 2025. PMID: 40274077
-
Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience.Eur J Haematol. 2024 Oct;113(4):477-484. doi: 10.1111/ejh.14258. Epub 2024 Jun 21. Eur J Haematol. 2024. PMID: 39031870
-
Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.Curr Opin Infect Dis. 2018 Aug;31(4):286-291. doi: 10.1097/QCO.0000000000000459. Curr Opin Infect Dis. 2018. PMID: 29746444 Review.
-
Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.Drugs Today (Barc). 2018 Jun;54(6):361-368. doi: 10.1358/dot.2018.54.6.2833982. Drugs Today (Barc). 2018. PMID: 29998227 Review.
Cited by
-
Understanding the Cytomegalovirus Cyclin-Dependent Kinase Ortholog pUL97 as a Multifaceted Regulator and an Antiviral Drug Target.Cells. 2024 Aug 13;13(16):1338. doi: 10.3390/cells13161338. Cells. 2024. PMID: 39195228 Free PMC article. Review.
-
CMV reactivation during pretransplantation evaluation: a novel risk factor for posttransplantation CMV reactivation.Blood Adv. 2024 Sep 10;8(17):4568-4580. doi: 10.1182/bloodadvances.2023012234. Blood Adv. 2024. PMID: 38924728 Free PMC article.
-
Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC).Mediterr J Hematol Infect Dis. 2024 Sep 1;16(1):e2024065. doi: 10.4084/MJHID.2024.065. eCollection 2024. Mediterr J Hematol Infect Dis. 2024. PMID: 39258183 Free PMC article. Review.
-
Cytomegalovirus Immune reconstitution in cord blood transplant recipients on letermovir prophylaxis.Transpl Infect Dis. 2023 Oct;25(5):e14104. doi: 10.1111/tid.14104. Epub 2023 Jul 12. Transpl Infect Dis. 2023. PMID: 37436771 Free PMC article.
-
Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus.Viruses. 2024 May 29;16(6):869. doi: 10.3390/v16060869. Viruses. 2024. PMID: 38932161 Free PMC article.
References
-
- Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85:10884–93. - PubMed - PMC - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical